<DOC>
	<DOCNO>NCT00550745</DOCNO>
	<brief_summary>The purpose study evaluate general safety ZOSTAVAX™ subject 60 year age old required FDA .</brief_summary>
	<brief_title>ZOSTAVAX™ Safety Study Subjects ≥ 60 Years Age ( V211-020 )</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>60+ year Age Signed informed consent prior start study NonFeverish , ( less 101.0°F / 38.3°C ) day vaccination Females must postmenopausal negative pregnancy test A history allergic reaction vaccine component ( include gelatin neomycin ) Prior receipt varicella zoster vaccine Any live virus vaccine administer within 4 week start study scheduled 42 day vaccination Any inactivate virus vaccine , except flu vaccine , administer within 7 day start study scheduled 42 day vaccination Subject pregnant breastfeeding Participation investigational drug vaccine study within last 30 day prior start study expect 42 day vaccination An ongoing illness ( include active untreated tuberculosis ) might interfere prevent subject completion study Use immunosuppressive therapy . Subjects take corticosteroid prednisone exclude . Excluded immunosuppressive therapy also include chemotherapeutic agent use treat cancer condition , treatment associate organ bone marrow transplantation Known suspect immune dysfunction cause medical condition cause . Examples medical condition associate immune dysfunction include congenital immunodeficiency , human immunodeficiency virus ( HIV ) infection , organ bone marrow transplantation , leukemia , lymphoma , Hodgkin 's disease , multiple myeloma , generalized malignancy . Subjects history cancer active treatment thought weaken immune system time enrollment eligible Any active use nontopical antiviral therapy include limited acyclovir , famciclovir , valacyclovir , ganciclovir , foscarnet , brivudine , cidofovir</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>